Estrella Immunopharma, Inc.
ESLAW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $249.2K in total; no superinvestor holds it.
Other share classesESLA
Q3 2024 vs. Q2 2024
How the institutions holding Estrella Immunopharma, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 626.0K | 812.2K | +186.2K (+29.7%) |
| Value | $44.9K | $75.4K | +$30.5K (+68.0%) |
New holders (1)
Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Atw Spac Management LLC | 183,099 | $16.2K | 0.02% |
Sold out (2)
Institutions that held Estrella Immunopharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| UBS Group AG | 5,090 | $183 |
| Bank of America Corp | 80 | $3 |